China Focus® It is a Chinese conference brand with the most global brand influence in the biopharmaceutical field. Its mission is to help Chinese enterprises connect with entrepreneurs, scientists, and investors in the life sciences sector from around the world.
2023year1month10day,China Focus® The Suzhou session of the Global Life Sciences Summit has officially commenced. Frost & SullivanFrost & SullivanMao Hua, Partner and Managing Director of Frost & Sullivan's Greater China Region, was invited to attend the event and participate in roundtable discussions. He also met with He Qijia, Vice President of Rongsheng Investment, and Chairman and Founder of Xueji Biotechnology.CEOZhu Fangfang, Deng Lingquan, a partner of Power Health Fund, and Zhang Xiaoliang, a partner of Taihao Venture Capital, discussed together "Capital winterBiotechSurvival Strategy".
Partner and Managing Director, Greater China, Frost & Sullivan fattening
2022The biomedical capital market has gradually corrected
2022In the capital market of the year, there has been a certain degree of reduction in both project amounts and numbers. Mao Hua said that the pullback in the entire secondary market for biotech companies did not occur entirely2022In2021Year-end pullbacks have already begun, and the trend has spread to the Sci-tech Innovation Board. However, looking only at the number of listed companies and the amount of financing,2022The year is not smaller than2021The age difference is quite significant. Due to the certain cycle involved in the listing process, some projects2020Year-end2021Launched at the beginning of the year, until2022The listing in [specific year] brought about a significant increase in the base number of existing listed companies.2022It is reflected in the years.
Enterprise supervision is becoming stricter, and the layout should be made as early as possible.
Capital providers and regulatory authorities are becoming increasingly strict in their review of the revenues and products of biotech companies. Mao Hua said that regulators will ask very detailed questions about the market valuation logic, product technical highlights, as well as the company's subsequent commercialization plans and steps.
Therefore, enterprises need to consider the commercialization, technological innovation, and originality of their products at an early stage. Mao Hua pointed out that how an enterprise survives, the clinical value and market value of drugs during competition, and the value after investment are all issues that capital providers are more concerned about. For capital providers, investment is not just about making a profit or chasing a trend; it is about hoping that the enterprise can become an important highlight and link in investment, thereby bringing returns on investment.
The key lies in the enterprise's own positioning, whether it isBiotechorBiopharma companyTherefore, it is particularly important to find the right development path
BiotechorBiopharma companyIt represents the development stage of the enterprise. Mao Hua believes that it is not an embodiment of corporate value itself, but rather more about the company's own positioning.
Mao Hua mentioned,BiotechThere may be many definitions, such as the following characteristics: First, it is necessary to have a complete team including R&D, production, and commercialization; second, there must be at least one product that has successfully achieved commercialization; third, there are financial indicators; fourth, there is a product accumulation and layout, such as an annual application forBLA,Non-Disclosure AgreementWhether there are products that can achieve clinical trial progress every year, or whether a positive product pipeline is established to support the future decline in market share of launched products, is an important indicator.
Biopharma companyfollowBiotechIn contrast, the required capabilities, resources, and products need to be differentiated, and not every enterprise is suitable forBiotechwalked toBiopharma companyTherefore, it is necessary to clearly understand one's own suitable positioning and then combine resources to fulfill the mission of enterprise development.
In the future, capital markets will place emphasis on 'value'
although2022The capital market has seen some corrections in the year, but there have also been some innovative breakthroughs. Mao Hua cited examples, mentioning that cell and gene therapy are currently developing rapidly but are still in their early stages, and commercialization requires continuous exploration.
All participants in the market are concerned about 'value', hoping that products can ultimately benefit patients and achieve clinical value. For enterprises, they need market value, revenue, and profits; investment institutions require investable value, hoping to see enterprise growth and ultimately bring products to clinical practice and patients; service providers also expect to provide more information and value, helping enterprises discover suitable tracks for themselves, demonstrate unique differentiated positioning, and find their own points of value promotion.
Mao Hua said that if the entire industry can return to 'value', it will also be beneficial for companies to enter the capital market in the future.
Frost & Sullivan medical has a wide base of corporate clients in China and in the past20A vast customer network was established within the year, with over200The project has accumulated a wealth of experience in various medical sub-fields. Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to offer one-stop solutions for enterprises in specialized sub-sectors such as pharmaceuticals and medical devices. Our services have received wide attention from investors.
